Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 4/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.33 |
| ▸ | SELE | P16581 | 4/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | USP4 | Q13107 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26582580 | 0.83 | HDAC8 (0.33) | TDP1L3MBTL1HDAC8ACACB | |
| SCHEMBL12344408 | 0.82 | ACACB (0.41) | APPHDAC8ACACB | |
| SCHEMBL29089308 | 0.82 | TSHR (0.46) | APPTDP1HDAC8 | |
| SCHEMBL16070964 | 0.79 | APP (0.37) | PTPN2PTPN1PTPN6APPTDP1 | |
| SCHEMBL15565141 | 0.79 | APP (0.42) | PTPN2PTPN1PTPN6APPNAAA | |
| SCHEMBL517636 | 0.79 | NR3C1 (0.40) | TDP1HDAC8USP4USP7ACACB | |
| SCHEMBL3016789 | 0.79 | HDAC8 (0.35) | TDP1L3MBTL1HDAC8USP4USP7 | |
| SCHEMBL18085581 | 0.78 | PTPN2 (0.41) | PTPN2PTPN1PTPN6APPTDP1 | |
| SCHEMBL14653334 | 0.78 | KDM4E (0.50) | APP | |
| SCHEMBL20569054 | 0.77 | L3MBTL1 (0.51) | APPTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268421-B1 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-6872834-B2 | Phenyl-substituted indoles and indazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1268421-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | IDO1, IDO2, AADAC | PTPN2 2947/4885PTPN1 3167/4885PTPN6 3021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.